Multiple mechanisms and applications of tertiary lymphoid structures and immune checkpoint blockade
Open Access
- 5 March 2025
- journal article
- review article
- Published by Springer Nature in Journal of Experimental & Clinical Cancer Research
- Vol. 44 (1) , 1-17
Abstract
Background: Immune checkpoint blockade (ICB) inhibits tumor immune escape and has significantly advanced tumor therapy. However, ICB benefits only a minority of patients treated and may lead to many immune-related adverse events. Therefore, identifying factors that can predict treatment outcomes, enhance synergy with ICB, and mitigate immune-related adverse events is urgently needed. Main text: Tertiary lymphoid structures (TLS) are ectopic lymphoid tissues that arise from the tumor periphery. They have been found to be associated with better prognosis and improved clinical outcomes after ICB therapy. TLS may help address the problems associated with ICB. The multiple mechanisms of action between TLS and ICB remain unknown. This paper described potential mechanisms of interaction between the two and explored their potential applications.Keywords
Funding Information
- Natural Science Foundation of China (82060566, 82160464)
- Jiangxi Provincial Outstanding Young Talents projects (2019BCB23020)
- Jiangxi Key Laboratory for Individualized Cancer Therapy (20202BCD42011)
This publication has 113 references indexed in Scilit:
- Single‐cell transcriptome sequencing of B‐cell heterogeneity and tertiary lymphoid structure predicts breast cancer prognosis and neoadjuvant therapy efficacyClinical and Translational Medicine, 2023
- Immune checkpoint inhibitor-related thyroid dysfunctionBest Practice & Research Clinical Endocrinology & Metabolism, 2022
- Neurological disorders associated with immune checkpoint inhibitors: an association with autoantibodiesCancer Immunology, Immunotherapy, 2021
- Alterations of DNA damage response pathway: Biomarker and therapeutic strategy for cancer immunotherapyActa Pharmaceutica Sinica B, 2021
- Diabetes mellitus induced by immune checkpoint inhibitorsDiabetes/Metabolism Research and Reviews, 2020
- Acquired Resistance to Immune Checkpoint InhibitorsCancer Cell, 2020
- Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical PearlsCurrent Oncology Reports, 2020
- The Single-Cell Phenotypic Identity of Human CD8+ and CD4+ T Cells2018
- Dermatologic Reactions to Immune Checkpoint InhibitorsAmerican Journal of Clinical Dermatology, 2017
- Characteristics and significance of colorectal cancer associated lymphoid reactionInternational Journal of Cancer, 2013